Chimerix Investor Conference Presentation Deck
Performance Status and Corticosteroid Use
21
Corticosteroid Response¹
Evaluable, N
Response rate, N(%)
(95% CI)
15
7 (47%)
(21 – 73%)
Time to response, months
median (range)
Performance Status Response²
Evaluable, N
Response rate, N(%)
(95% CI)
Time to response, months
median (range)
3.7
(1.9-5.6)
34
7 (21%)
(9 - 38%)
3.5
(1.9 -22.4)
Total Dex Dose (mg)
12
11
10
9
00
8
6
сл
4
3-
2
1
0
0
1
2
3
Corticosteroids³
4
5
Months from First Dose
6
7
8
¹Corticosteroid response: 250% reduction in average daily corticosteroid dose compared to baseline with stable or improved KPS/LPS. Must be confirmed at
next analysis timepoint. Corticosteroids were converted into a dexamethasone equivalent dose. Baseline 24mg dexamethasone at baseline were evaluable.
2Performance status response: increase in KPS/LPS compared to baseline with stable or reduced corticosteroid use. Must be confirmed at next analysis
timepoint. Baseline KPS/LPS ≤80 were evaluable.
³Average daily over 1 week around analysis window presented (every 8 weeks)
9View entire presentation